Bumped-Kinase Inhibitors as Castrate-Resistant Prostate Cancer Drugs

Abstract

Kinase inhibitors present exciting therapies for cancer including prostate cancer. We have developed a class of kinase inhibitors, bumped kinase inhibitors (BKIs), that have narrow kinase specificity due to their unique binding of the ATP-binding site and activity against androgen receptor (AR) positive prostate cancer cells. Despite of the life extending therapies of the newest drugs targeting the AR e.g. abiraterone and enzalutamide, tumors almost universally acquire resistance, and survival is extended by only four months.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2022
Accession Number
AD1213949

Entities

People

  • Wesley C. Van Voorhis

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Androgen Receptors
  • Androgens
  • Biochemistry
  • Biomedical Research
  • Chemistry
  • Department Of Defense
  • Inhibitors
  • Law
  • Lead Compounds
  • Neoplasms
  • Patent Applications
  • Patents
  • Prostate
  • Prostate Cancer
  • Students
  • Universities

Fields of Study

  • Biology

Readers

  • Educational Psychology
  • Prostate Cancer Biology.